Prapimporn Chattranukulchai Shantavasinkul

Dr. Prapimporn Chattranukulchai Shantavasinkul

Associate Professor, Chief Division of Nutrition and Biochemical Medicine Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University 270 Rama VI Rd., Ratchatewi, Bangkok 10400, Thailand
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
PSPrapimporn Chattranukulchai Shantavasinkul
Prapimporn Chattranukulchai Shantavasinkul
TTTerapong Tantawichien
Terapong Tantawichien
SWSupaporn Wacharapluesadee
Supaporn Wacharapluesadee
AJAnuruck Jeamanukoolkit
Anuruck Jeamanukoolkit
PUPiyada Udomchaisakul
Piyada Udomchaisakul
THThiravat Hemachudha
Thiravat Hemachudha
We report an atypical case of paralytic rabies presenting with trismus followed by limb weakness, areflexia, ophthalmoparesis, and bilateral ptosis.

1 January 2010 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
PSPrapimporn Chattranukulchai Shantavasinkul
Prapimporn Chattranukulchai Shantavasinkul
HWHenry Wilde
Henry Wilde
ASArtikaya Sawangvaree
Artikaya Sawangvaree
AKApinya Kumchat
Apinya Kumchat
NRNatthasri Ruksaket
Natthasri Ruksaket
TTTerapong Tantawichien
Terapong Tantawichien
Background. Patients exposed to a rabid animal often travel long distances to receive postexposure prophylaxis (PEP), which requires 4 or 5 visits. Red

9 March 2023 in The American Journal of Clinical Nutrition
Verified
Journal Article
Open access
Chanita UnhapipatpongChanita Unhapipatpong
Chanita Unhapipatpong
NPNint Polruang
Nint Polruang
PSPrapimporn Chattranukulchai Shantavasinkul
Prapimporn Chattranukulchai Shantavasinkul
NJNarachai Julanon
Narachai Julanon
PNPawin Numthavaj
Pawin Numthavaj
ATAmmarin Thakkinstian
Ammarin Thakkinstian
Curcumin supplementation may promote weight loss and ameliorate obesity-related complications through its antioxidative and anti-inflammatory properties. An umbrella review and updated meta-analysis of randomized controlled trials (RCTs) was conducted to evaluate the effect of curcumin supplementation on anthropometric indices. Systematic reviews and meta-analyses (SRMAs) of RCTs were identified from electronic databases (Medline, Scopus, Cochrane, and Google Scholar) up to 31 March, 2022, without language restriction. SRMAs were included if they assessed curcumin supplementation on any of the following: BMI, body weight (BW), or waist circumference (WC). Subgroup analyses were performed, stratifying by patient types, severity of obesity, and curcumin formula. The study protocol was a priori registered. From an umbrella review, 14 SRMAs with 39 individual RCTs were included with a high degree of overlap. In addition, searching was updated from the last search of included SRMAs in April 2021 up to 31 March, 2022, and we found 11 additional RCTs, bringing the total up to 50 RCTs included in the updated meta-analyses. Of these, 21 RCTs were deemed of high risk of bias. Curcumin supplementation significantly reduced BMI, BW, and WC with mean differences (MDs) of -0.24 kg/m2 (95% CI: -0.32, -0.16 kg/m2), -0.59 kg (95% CI: -0.81, -0.36 kg), and -1.32 cm (95% CI: -1.95, -0.69 cm), respectively. The bioavailability-enhanced form reduced BMI, BWs, and WC more, with MDs of -0.26 kg/m2 (95% CI: -0.38, -0.13 kg/m2), -0.80 kg (95% CI: -1.38, -0.23 kg) and -1.41 cm (95% CI: -2.24, -0.58 cm), respectively. Significant effects were also seen in subgroups of patients, especially in adults with obesity and diabetes. Curcumin supplementation significantly reduces anthropometric indices, and bioavailability-enhanced formulas are preferred. Augmenting curcumin supplement with lifestyle modification should be an option for weight reduction. This trial was registered at PROSPERO as CRD42022321112 (https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022321112).

4 May 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
Chanita UnhapipatpongChanita Unhapipatpong
Chanita Unhapipatpong
PSPrapimporn Chattranukulchai Shantavasinkul
Prapimporn Chattranukulchai Shantavasinkul
VKVijj Kasemsup
Vijj Kasemsup
SSSukanya Siriyotha
Sukanya Siriyotha
DWDaruneewan Warodomwichit
Daruneewan Warodomwichit
ATAmmarin Thakkinstian
Ammarin Thakkinstian
The health effects of saturated fat, particularly tropical oil, on cardiovascular disease are unclear. We investigated the effect of tropical oil (palm and coconut oils), lard, and other common vegetable oils (soybean and rice bran oils) that are widely used in tropical and Asian countries on lipid profiles. We performed an umbrella review of meta-analyses and systematic reviews. Electronic databases (Medline, Scopus, Embase, and Cochrane) were searched up to December 2018 without language restriction. We identified nine meta-analyses that investigated the effect of dietary oils on lipid levels. Replacement of polyunsaturated fatty-acid-rich oils (PUFAs) and monounsaturated FA-rich oils (MUFAs) with palm oil significantly increased low-density lipoprotein cholesterol (LDL-c), by 3.43 (0.44–6.41) mg/dL and 9.18 (6.90–11.45) mg/dL, respectively, and high-density lipoprotein cholesterol (HDL-c), by 1.89 (1.23–2.55) mg/dL and 0.94 (−0.07–1.97) mg/dL, respectively. Replacement of PUFAs with coconut oil significantly increased HDL-c and total cholesterol –by 2.27 (0.93–3.6) mg/dL and 5.88 (0.21–11.55) mg/dL, respectively—but not LDL-c. Substituting lard for MUFAs and PUFAs increased LDL-c–by 8.39 (2.83–13.95) mg/dL and 9.85 (6.06–13.65) mg/dL, respectively—but not HDL-c. Soybean oil substituted for other PUFAs had no effect on lipid levels, while rice bran oil substitution decreased LDL-c. Our findings show the deleterious effect of saturated fats from animal sources on lipid profiles. Replacement of unsaturated plant-derived fats with plant-derived saturated fats slightly increases LDL-c but also increases HDL-c, which in turn may exert a neutral effect on cardiovascular health.

27 November 2020 in BMJ Supportive & Palliative Care
Verified
Journal Article
Closed access
PDF file
MSManit Saeteaw
Manit Saeteaw
PSPhitjira Sanguanboonyaphong
Phitjira Sanguanboonyaphong
JYJukapun Yoodee
Jukapun Yoodee
KCKaitlyn Craft
Kaitlyn Craft
RSRatree Sawangjit
Ratree Sawangjit
NCNathorn Chaiyakunapruk
Nathorn Chaiyakunapruk
Aims: Randomised controlled trials (RCTs) demonstrated benefits of pharmacological interventions for cachexia in improving weight and appetite. However, comparative efficacy and safety are not available. We conducted a systematic review and network meta-analysis (NMA) to evaluate the relative efficacy and safety of pharmacological interventions for cachexia.Methods: PubMed, EmBase, Cochrane, and ClinicalTrials.gov were searched for RCTs until October 2019. Key outcomes were total body weight (TBW) improvement, appetite (APP) score and serious adverse events. Two reviewers independently extracted data and assessed risk of bias. NMA was performed to estimate weight gain and APP score increase at 8 weeks, presented as mean difference (MD) or standardised MD with 95% CI.Results: 80 RCTs (10 579 patients) with 12 treatments were included. Majority is patients with cancer (7220). Compared with placebo, corticosteroids, high-dose megestrol acetate combination (Megace_H_Com) (≥400 mg/day), medroxyprogesterone, high-dose megestrol acetate (Megace_H) (≥400 mg/day), ghrelin mimetic and androgen analogues (Androgen) were significantly associated with MD of TBW of 6.45 (95% CI 2.45 to 10.45), 4.29 (95% CI 2.23 to 6.35), 3.18 (95% CI 0.94 to 5.41), 2.66 (95% CI 1.47 to 3.85), 1.73 (95% CI 0.27 to 3.20) and 1.50 (95% CI 0.56 to 2.44) kg. For appetite improvement, Megace_H_Com, Megace_H and Androgen significantly improved standardised APP score, compared with placebo. There is no significant difference in serious adverse events from all interventions compared with placebo.Conclusions: Our findings suggest that several pharmacological interventions have potential to offer benefits in treatment of cachexia especially Megace_H and short-term use corticosteroids. Nonetheless, high-quality comparative studies to compare safety and efficacy are warranted for better management of cachexia.

1 February 2018 in Nutrition
Verified
Journal Article
Closed access
OPOrawan Pichitchaipitak
Orawan Pichitchaipitak
SCSineenuch Ckumdee
Sineenuch Ckumdee
SASiriluk Apivanich
Siriluk Apivanich
DCDarunee Chotiprasitsakul
Darunee Chotiprasitsakul
PSPrapimporn Chattranukulchai Shantavasinkul
Prapimporn Chattranukulchai Shantavasinkul